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Abstract
Background: BRCA1 is a main component of homologous recombination and induces resistance to platinum in
preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate
the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit
BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the
recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model.
Methods: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung
cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of
BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as
cut-off point.
Results: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival
of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months
in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median
OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but
high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology
Group performance status 0–1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of
progression (p = 0.03) and of death (p = 0.004).
Conclusions: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the
sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the
way for further refinement of the BRCA1 predictive model.
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Background
Platinum-based chemotherapy is currently the first-line
treatment of choice for patients with advanced non-small-
cell lung cancer (NSCLC) in the presence of wild-type epi-
dermal growth factor receptor and non-rearranged ALK.
However, no reliable predictive biomarkers of platinum
resistance are currently available for routine clinical use.
Breast cancer susceptibility gene 1 (BRCA1) plays a pivotal
role in the repair of platinum-induced DNA damage and
has been associated with cell resistance to platinum in
preclinical models [1–3]. From the biological point of
view, BRCA1 is involved in two main mechanisms of
repair of platinum-induced DNA damage. The first
one is nucleotide excision repair (NER), being the main
pathway for the repair of helix-distorting DNA lesions
[4, 5]. The second one is homologous recombination, an
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error-free mechanism for the repair of DNA double-
strand breaks [6].
In clinical retrospective series, low mRNA expression
of BRCA1 was associated with longer survival in NSCLC
patients treated with cisplatin-based neoadjuvant
chemotherapy [7], while the clinical feasibility of pro-
spectively assessing BRCA1 mRNA expression was later
demonstrated in a prospective phase II trial in advanced
NSCLC patients [8]. Despite these encouraging prelimin-
ary results, a phase III randomized trial (NCT00617656/
GECP-BREC) comparing non-biomarker-directed therapy
with treatment based on the mRNA expression levels of
BRCA1 and receptor-associated protein 80 (RAP80) was
recently closed prematurely, since the interim analysis
showed a detrimental effect in terms of progression free
survival (PFS) in patients allocated to the experimental
arm (hazard ratio [HR], 1.35; p = 0.03) [9, 10]. The protein
RAP80 is a component of one of the BRCA1 complexes at
DNA damage sites and may be essential in the assembly
of the BRCA1-A complex at DNA damage sites [11].
Retrospective analyses had demonstrated that RAP80
mRNA expression could affect the predictive capacity of
BRCA1 [8, 12].
However, several other DNA repair components are
required for the recruitment and the function of BRCA1
in DNA repair [13, 14]. In particular, post-translational
protein modification called ubiquitination is fundamen-
tal for the assembly of effector proteins complexes. After
the phosphorylation of mediator of DNA damage check-
point 1 (MDC1), RING finger ubiquitin ligase 8 (RNF8)
is recruited at DNA damage sites and creates a complex
with ubiquitin conjugating enzyme 13 (UBC13). This
complex induces the formation of Lys 63-linked ubiqui-
tin chains, which are essential for the assembly of
BRCA1 complexes at double-strand breaks [15–17]. Re-
cently, HECT domain and RCC1-like domain-containing
protein 2 (HERC2), which functions as an E3-ubiquitin
ligase, was shown to facilitate the formation of the
RNF8-UBC13 complex [18] (Fig. 1). The protein HERC2
is also involved in regulating the stability of BRCA1 at
DNA damage sites, since HERC2 ubiquitinates BRCA1
and targets it for degradation when BRCA1 is not in a
complex with BRCA1-associated RING domain protein
1 (BARD1). The BRCA1-BARD1 heterodimer is required
for BRCA1 stability, nuclear localization and E3 ligase
function [19, 20]. This role of HERC2 is enhanced in the
S-phase of the cell cycle, thus contributing to the modu-
lation of BRCA1 function throughout the cell cycle and
to the role of BRCA1 at the G2-M checkpoint [21].
On the basis of this biological model, we hypothesized
that RNF8, UBC13 and HERC2, being the main pro-
tagonists of ubiquitination process leading to BRCA1
recruitment at DNA damage sites, could modulate
the predictive model based on BRCA1 expression.
Methods
We retrospectively analyzed a series of 71 patients diag-
nosed with advanced NSCLC and treated with cisplatin
or carboplatin plus gemcitabine or pemetrexed in the
first-line setting (Table 1). Patients were selected accord-
ing to first-line treatment, not including taxanes or vinca
alkaloids, and availability of adequate tumor samples. No
further clinical selection was performed. Radiological
response was assessed using the Response Evaluation
Criteria for Solid Tumor (RECIST) v 1.0 [22]. Progression
free survival (PFS) was calculated from the beginning of
first-line treatment until demonstrated radiological pro-
gression or death from any cause. The overall survival
(OS) was calculated from the start of platinum-based
chemotherapy to death from any cause.
Paraffin-embedded tumor specimens were collected
before beginning chemotherapy and patients who had
previously received radiotherapy were excluded. Tumor
samples were evaluated by the pathologist to ensure a
minimum of 90 % of tumor cells in analyzed samples.
After mRNA extraction and retro transcription, the
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Fig. 1 The protein BRCA1 is recruited at DNA damage through a
recognition mechanism implying the phosphorylation of histone
H2AX and leading to the assembly of a protein complex that
induces histones post-translational modification called ubiquitination.
This protein complex includes the RING finger ubiquitin ligase 8
(RNF8), the conjugating enzyme 13 (UBC13) and the E3 ubiquiting
ligase HECT domain-containing protein 2 (HERC2). The biological
model of BRCA1 recruitment at DNA damage sites was used to
select the genes to evaluate as potential predictive markers of
platinum sensitivity in lung cancer
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mRNA expression levels of BRCA1, RNF8, UBC13 and
HERC2 were quantified using real-time PCR with a com-
parative method, as previously described [8]. mRNA
levels were considered as categorical variables and di-
chotomized using the median value as cut-off point
(Additional file 1: Supplementary Methods).
The median PFS and OS were estimated using the
Kaplan-Meier method and compared with a two-sided log-
rank test. Multivariate analyses were performed with the
Cox regression method, with Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (PS) as covariate.
All statistical analyses were performed using Statistical
Package for Social Science (SPSS) for Windows ver-
sion 17 (Chicago, IL, USA). Significance was set at
p < 0.05.
Results and discussion
The clinical features of the study population are summa-
rized in Table 1. Patients were mainly male (76 %),
asymptomatic or poorly symptomatic at diagnosis
(ECOG PS 0–1, 75 %), and current or former smokers
(85 %). The prevalent histology was adenocarcinoma
(60 %). First-line treatment was chosen according to
standard clinical practice and did not include taxanes or
vinca alkaloids (Table 1).
The expression of each gene was successfully analyzed
in 87-96 % of patients (Additional file 2: Table S1).
The median PFS for all 71 patients was 7.2 months
(95 % confidence interval, CI = 5.8-8.5) and the median
OS was 10.7 months (95 % CI = 9.2-12.2) (Additional
file 3: Figure S1). No differences in PFS or OS were
observed according to the individual expression levels
of any of the four genes.
Based on our previous experience [23], we then exam-
ined the potential predictive value of a two-gene model
and analyzed PFS and OS according to the combination
of BRCA1 with each of the three other genes. No signifi-
cant differences were observed according to the combin-
ation of BRCA1 and UBC13 or of BRCA1 and RNF8
expression levels. However, the combination of BRCA1
and HERC2 identified subgroups of patients with differ-
ent outcomes. Reliable quantification of mRNA was
available for 55 patients. Among patients expressing
low levels of BRCA1, the median PFS was 7.4 months
(95 % CI = 4.5-10.4) for those expressing low HERC2
levels, compared to 5.9 months (95 % CI = 4.8-7.1) for
patients with high HERC2 levels (p = 0.01) (Fig. 2a).
The median OS was 15.3 months (95 % CI = 5.5-25.8)
for patients expressing low BRCA1 and HERC2 and
7.4 months (95%CI = 5.1-9.7) for those with low
BRCA1 but high HERC2 levels (p = 0.008) (Fig. 2b).
Consistently, response rates were 42.9 % in patients
expressing low levels of both BRCA1 and HERC2 and
28.6 % in those with low BRCA1 but high HERC2
levels. Progressive disease was recorded as best radio-
logical response in 23.8 % and 42.9 % of patients, re-
spectively (Additional file 4: Table S2). In contrast,
HERC2 expression levels did not affect the outcome
of patients expressing high levels of BRCA1 (Additional
file 5: Figure S2).
To confirm the predictive value of this model, we
assessed multivariate analysis and selected a more homo-
geneous population according to performance status (PS).
Multivariate analyses showed that among patients with
ECOG PS 0–1, high levels of either BRCA1 or HERC2
were associated with an increased risk of progression (HR,
Table 1 Characteristics of 71 patients with advanced non-small-
cell lung cancer
N (%)
Age median (range) 63 (40–82)
Gender
Male 54 (76)
Female 17 (24)
ECOG PS
0 9 (13)
1 44 (62)
2 13 (18)
No data 5 (7)
Smoking status
Current smoker 31 (44)
Former smoker 29 (41)
Never smoked 11 (15)
Histology
Adenocarcinoma 43 (60)
Squamous cell carcinoma 14 (20)
Large cell carcinoma 14 (20)
First-line treatment
Cisplatin-gemcitabine 32 (45)
Carboplatin-gemcitabine 19 (27)
Cisplatin-pemetrexed 10 (14)
Carboplatin-pemetrexed 10 (14)
Second-line treatment
Taxanes 11 (15)
EGFR TKIs 22 (31)
Others 9 (13)
Response rate
Complete response 0 (0)
Partial response 27 (38)
Stable disease 26 (37)
Progressive disease 11 (30)
No data 7 (10)
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1.4; 95 % CI = 1.1-4.73; p = 0.03) and death (HR, 3.7; 95 %
CI = 1.54-9.1; p = 0.004) (Table 2), while among patients
with PS 2, no significant differences according to BRCA1
and HERC2 levels were observed.
The identification of predictive markers of platinum
sensitivity in lung cancer can help optimize the chemo-
therapy approach in advanced NSCLC patients. While a
defective DNA damage repair capacity is associated with
increased sensitivity to platinum, the translational appli-
cation of this concept is rather difficult due to the com-
plicated interplay among DNA repair pathways [13,
14]. The potential predictive roles of BRCA1 and ex-
cision repair cross-complementing 1 (ERCC1) have
been widely studied in NSCLC [14, 24]. ERCC1 is a
main component of NER, and low ERCC1 protein
and mRNA expression have been associated with im-
proved outcome in platinum-treated NSCLC patients,
both in early-stage and in metastatic disease [14, 24].
However, neither BRCA1 nor ERCC1 expression was
confirmed as a predictive marker in phase III studies
[9, 25]. Nevertheless, our knowledge of DNA repair
pathways is increasing, and a pivotal role has been
demonstrated for post-translational modification in
the response to double-strand breaks. In particular,
the proteins UBC13 and RNF8, and more recently
HERC2, are known to be essential for the recruitment
of BRCA1 at DNA damage sites [13, 15–18].
The present study examined the hypothesis that the
BRCA1 predictive model in advanced NSCLCs could be
improved through the analysis of genes involved in the
recruitment of BRCA1 at DNA damage sites through
post-translational modifications (Fig. 1). In a retrospective,
clinically homogeneous series of patients, we have demon-
strated that HERC2 mRNA expression provides additional
predictive information when analyzed in conjunction with
BRCA1. The outcome of patients expressing low BRCA1
mRNA was significantly different according to HERC2
mRNA expression and the median OS in patients express-
ing low levels of both BRCA1 and HERC2 was
15.3 months, which is greatly superior to that observed in
unselected patients treated with platinum-based therapy
(rarely exceeding 10 months) [26]. Moreover, a signifi-
cantly increased risk both of progression and of death was
associated with high expression of either BRCA1 or
HERC2 with Cox regression analysis.
Fig. 2 (a) Progression-free survival and (b) overall survival in 30 patients with low BRCA1 levels (lower than the median value) according to
HERC2 levels
Table 2 Multivariate analyses of progression-free and overall
survival in 53 patients with ECOG PS 0-1
Progression-free survival
Hazard ratio 95 % CI P-value
Performance status
0 1.00 (referent)
1 1.45 0.62-3.41 0.39
BRCA1/HERC2 expression
Low/Low 1 (referent)
Other combinations 1.45 1.10-4.73 0.03
Overall survival
Hazard ratio 95 % CI P-value
Performance status
0 1 (referent)
1 1.35 0.45-4.1 0.58
BRCA1/HERC2 expression
Low/Low 1 (referent)
Other combinations 3.70 1.54 -9.10 0.004
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These findings lend support to the integrated analysis
of several DNA repair components, which can provide
enhanced results compared to the analysis of one com-
ponent alone. Moreover, our results show the important
role of HERC2 in determining platinum sensitivity in
patients with low BRCA1 expression, which is consistent
with its known role in the recruitment of BRCA1 at
DNA damage sites [18].
The main limitations of the study are its retrospective
nature and the relatively small number of patients with
mRNA expression data available for both BRCA1 and
HERC2. Due to the number of patients, we cannot draw
definitive conclusions about the absence of predictive
value of UBC13 and RNF8 in combination with BRCA1 or
of each gene when considered in isolation. In addition,
mRNA expression data could not able to mirror the pro-
tein function and a validation through analyses of these
markers at protein level could further increase the interest
of these data. However, mRNA analysis is one of the most
used surrogate marker of DNA repair capacity, taking into
account the great difficulties in measuring DNA repair
capacity at functional level. From the practical point of
view, the need of highly experienced laboratories is one
main limitation to the use of mRNA quantitative expres-
sion, while the possibility of testing more candidate
markers is one strength point that could be particularly
useful when studying a complex molecular pathway and
the interplay of different components of the pathway.
Further development of this research would be the
validation of the findings in a larger series of patients
and the inclusion of a validation set of patients treated
without platinum in order to test the hypothesis of a
prognostic effect for the studied model. Finally the data
should be confirmed prospectively.
Conclusions
In our study population, integrated mRNA analysis of
BRCA1 and HERC2 shows a predictive role in advanced
NSCLC patients treated with first-line platinum-based
chemotherapy. The patients expressing low levels of
both genes achieved better outcome to platinum, while
isolated analysis of BRCA1 does not carry predictive
value. Despite the limitations of the study, our results
identify a new potential predictive marker, HERC2, and
further refine the BRCA1 predictive model. Importantly,
our findings support and pave the way for additional
biomarker analyses, potentially useful for customizing
chemotherapy in lung cancer.
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